Presentation on theme: "2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults Developed in Collaboration with the American Society of Echocardiography,"— Presentation transcript:
12010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults Developed in Collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance
2CitationThis slide set was adapted from the 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults (Journal of the American College of Cardiology). Published ahead of print on XXX, 2010, available at:The full-text guidelines are also available on the following Web sites:ACC (www.cardiosource.org) and,AHA (www.americanheart.org)
3Special Thanks To Slide Set Editors Nanette K. Wenger, MD and Philip Greenland, MDThe Guideline for CV Risk Assessment in Asymptomatic Adults Writing Committee MembersPhilip Greenland, MD, FACC, FAHA, ChairJoseph S. Alpert, MD, FACC, FAHAGeorge A. Beller, MD, MACC, FAHAEmelia J. Benjamin, MD, ScM, FACC, FAHA*†Matthew J. Budoff, MD, FACC, FAHA‡§║Zahi A. Fayad, PhD, FACC, FAHA¶Elyse Foster, MD, FACC, FAHA#Mark A. Hlatky, MD, FACC, FAHA§**John McB. Hodgson, MD, FACC, FAHA, FSCAI‡§**††Frederick G. Kushner, MD, FACC, FAHA†‡‡Michael S. Lauer, MD, FACC, FAHALeslee J. Shaw, PhD, FACC, FAHA§§Sidney C. Smith, Jr., MD, FACC, FAHA║║¶¶Allen J. Taylor, MD, FACC, FAHA##William S. Weintraub, MD, FACC, FAHANanette K. Wenger, MD, MACC, FAHA*ACCF/AHA Task Force on Performance Measures Liaison; †Recused from Section , Lipoprotein-Associated Phospholipase A2; ‡ Recused from Section , Coronary Computed Tomography Angiography; §Recused from Section , Diabetes Mellitus; ║SAIP Representative; ¶SCMR Representative; #ASE Representative; **Recused from Section , Computed Tomography for Coronary Calcium; †† SCAI Representative; ‡‡Recused from Section 2.3., Lipoprotein and Apolipoprotein Assessments; §§ASNC Representative; ║║ACCF/AHA Task Force on Practice Guidelines Liaison; ¶¶Recused from Section , Recommendations for Measurement of C-Reactive Protein; ##SCCT Representative.
4Classification of Recommendations and Levels of Evidence *Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.†For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
5Icons representing the Classification and Evidence Levels for Recommendations IIaIIbIIIBIIIaIIbIIIIIIaIIbIIIIIIaIIbIIIABIIIaIIbIIIIIIaIIbIIIIIIaIIbIIIABIIIaIIbIIIIIIaIIbIIIIIIaIIbIIIABIIIaIIbIIIIIIaIIbIII
6Key Considerations when Testing for CV Risk Efficacy of test procedure in assignment of risk statusShort-term riskLong-term riskIndependent statistical association with risk beyond traditional readily available inexpensive risk markersIncremental predictive value of testEffect on reclassification of risk compared to traditional risk factors aloneAccuracy and reproducibility of testRequirement for serial testing, which may be indicated to assess risk accurately for some tests2010 ACCF/AHA Guideline, JACC 55:e27, 2010
7Key Considerations when Testing for CV Risk (continued) Cost of test or procedureFinancialTest risksEffect on performance of added testingNoninvasive, invasivePost-test referral biasEffect on initiation of interventionsLifestylePharmacologicEffect on individual undergoing testingEmotionalEffect on outcomesShort-termLong-term
8Opportunity for Early Preventive Interventions Long asymptomatic latent period of Coronary Heart Disease (CHD)Half of all cardiovascular sudden death not preceded by cardiac symptoms, diagnosesHigh prevalence of atherosclerotic risk factors in US populationMethodology available to evaluate prognostic value of risk factors, risk markersTarget intensity of intervention to severity of riskLower the high burden of coronary death in asymptomatic adults
9Recommended Approaches to Risk Stratification Guideline for Cardiovascular Risk Assessment in Asymptomatic AdultsRecommended Approaches to Risk Stratification
10General Approaches to Risk Stratification Recommended Approaches to Risk StratificationGeneral Approaches to Risk Stratification
11Recommendations for General Approaches to Risk Stratification Global risk scores (such as the Framingham Risk Score [FRS]) that use multiple traditional cardiovascular risk factors should be obtained for risk assessment in all asymptomatic adults without a clinical history of CHD. These scores are useful for combining individual risk factor measurements into a single quantitative estimate of risk that can be used to target preventive interventions.BIIIaIIbIII
12Comparison of a Sample of Global Coronary and Cardiovascular Risk Scores FraminghamSCOREPROCAM (Men)Reynolds (Women)Reynolds (Men)Sample size5345205,178538924,55810,724Age, range (y)30 to 74; M:4919 to 80; M:4635 to 65; M:47>45; M:52>50; M:63Mean follow-up (y)12131010.210.8Risk factorsconsideredAge, sex, totalcholesterol, HDLcholesterol,smoking, systolicblood pressure,antihypertensiveMedicationsAge, sex, total-HDL cholesterolratio, smoking,systolic bloodpressureAge, LDLfamily history,diabetes,triglyceridesAge, HbA1C (withdiabetes), smoking,systolic blood pressure,total cholesterol, HDLcholesterol, hsCRP,parental history of MIat <60 y of ageAge, systolic bloodpressure, totalcholesterol, smoking,hsCRP, parental historyof MI at <60 y of ageEndpointsCHD (MI andCHD death)Fatal CHDFatal/nonfatalMI or suddencardiac death(CHD and CVDcombined)MI, ischemic stroke,coronaryrevascularization,cardiovascular deathMI, stroke, coronaryURLs for riskcalculatorshin.net/atpiii/calculator.asp?usertype=prof ore.org/pages/welcome.aspx taskforce.com/coronary_risk_assessment.htmlkscore.org/ Note: Table 2 in full-text Guideline
13Family History and Genomics Recommended Approaches to Risk StratificationFamily History and Genomics
14Recommendations for Family History and Genomic Testing Family history of atherothrombotic cardiovascular disease (CVD) should be obtained for cardiovascular risk assessment in all asymptomatic adults.Genotype testing for CHD risk assessment in asymptomatic adults is not recommended.BIIIaIIbIIIBIIIaIIbIII
15Lipoprotein and Apolipoprotein Assessments Recommended Approaches to Risk StratificationLipoprotein and Apolipoprotein Assessments
16Recommendation for Lipoprotein and Apolipoprotein Assessments Measurement of lipid parameters, including lipoproteins, apolipoproteins, particle size, and density, beyond a standard fasting lipid profile is not recommended for cardiovascular risk assessment in asymptomatic adults.IIIaIIbIII
17Other Circulating Blood Markers and Associated Conditions Recommended Approaches to Risk StratificationOther Circulating Blood Markers and Associated Conditions
18Recommendation for Natriuretic Peptides BIIIaIIbIIIMeasurement of natriuretic peptides is not recommended for CHD risk assessment in asymptomatic adults.
19Recommendations for Measurement of C-Reactive Protein (CRP) BIIIaIIbIIIIn men 50 years of age or older or women 60 years of age or older with LDL cholesterol less than 130 mg/dL; not on lipid-lowering, hormone replacement, or immunosuppressant therapy; without clinical CHD, diabetes, chronic kidney disease, severe inflammatory conditions, or contraindications to statins, measurement of CRP can be useful in the selection of patients for statin therapy.
20Recommendations for Measurement of C-Reactive Protein (continued) BIIIaIIbIIIIn asymptomatic intermediate-risk men 50 years of age or younger or women 60 years of age or younger, measurement of CRP may be reasonable for cardiovascular risk assessment.In asymptomatic high-risk adults, measurement of CRP is not recommended for cardiovascular risk assessment.In low-risk men younger than 50 years of age or women 60 years of age or younger, measurement of CRP is not recommended for cardiovascular risk assessment.BIIIaIIbIIIBIIIaIIbIII
21Recommendation for Measurement of Hemoglobin A1C IIaIIbIIIMeasurement of hemoglobin A1C (HbA1C) may be reasonable for cardiovascular risk assessment in asymptomatic adults without a diagnosis of diabetes.
22Recommendations on testing for Microalbuminuria (Urinary Albumin Excretion) In asymptomatic adults with hypertension or diabetes, urinalysis to detect microalbuminuria is reasonable for cardiovascular risk assessment.In asymptomatic adults at intermediate risk without hypertension or diabetes, urinalysis to detect microalbuminuria might be reasonable for cardiovascular risk assessment.BIIIaIIbIIIBIIIaIIbIII
23Recommendation for Lipoprotein-associated Phospholipase A2 Lipoprotein-associated phospholipase A2 (Lp-PLA2) might be reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults.BIIIaIIbIII
24Cardiac and Vascular Tests for Risk Assessment in Asymptomatic Adults Recommended Approaches to Risk StratificationCardiac and Vascular Tests for Risk Assessment in Asymptomatic Adults
25Recommendations for Resting Electrocardiogram A resting electrocardiogram (ECG) isreasonable for cardiovascular risk assessmentin asymptomatic adults with hypertension ordiabetes.A resting ECG may be considered forcardiovascular risk assessment inasymptomatic adults without hypertension orIIIaIIbIIIIIIaIIbIII
26Recommendation for Transthoracic Echocardiogram Echocardiography to detect left ventricular hypertrophy may be considered for cardiovascular risk assessment in asymptomatic adults with hypertension.Echocardiography is not recommended for cardiovascular risk assessment of CHD in asymptomatic adults without hypertension.BIIIaIIbIIIIIIaIIbIII
27Recommendation for Measurement of Carotid Intima-Media Thickness Measurement of carotid artery intima-media thickness is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk. Published recommendations on required equipment, technical approach, and operator training and experience for performance of the test must be carefully followed to achieve high-quality results.BIIIaIIbIII
28Recommendation for Brachial / Peripheral Flow-mediated Dilation Peripheral arterial flow-mediated dilation studies are not recommended for cardiovascular risk assessment in asymptomatic adults.BIIIaIIbIII
29Recommendation for Specific Measures of Arterial Stiffness Measures of arterial stiffness outside of research settings are not recommended for cardiovascular risk assessment in asymptomatic adults.IIIaIIbIII
30Recommendation for Measurement of Ankle-Brachial Index IIaIIbIIIMeasurement of ankle-brachial index is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk.
31Recommendation for Exercise Electrocardiography An exercise ECG may be considered for cardiovascular risk assessment in intermediate-risk asymptomatic adults (including sedentary adults considering starting a vigorous exercise program), particularly when attention is paid to non-ECG markers such as exercise capacity.BIIIaIIbIII
32Recommendation for Stress Echocardiography Stress echocardiography is not indicated for cardiovascular risk assessment in low- or intermediate-risk asymptomatic adults. (Exercise or pharmacological stress echocardiography is primarily used for its role in advanced cardiac evaluation of symptoms suspected of representing CHD and/or estimation of prognosis in patients with known CAD or the assessment of subjects with valvular heart disease.)IIIaIIbIII
33Recommendations for Myocardial Perfusion Imaging Stress MPI may be considered for advanced cardiovascular risk assessment in asymptomatic adults with diabetes or asymptomatic adults with a strong family history of CHD or when previous risk assessment testing suggests high risk of CHD, such as a coronary artery calcium (CAC) score of 400 or greater.Stress MPI is not indicated for cardiovascular risk assessment in low- or intermediate-risk asymptomatic adults. (Exercise or pharmacologic stress MPI is a technology primarily used and studied for its role in advanced cardiac evaluation of symptoms suspected of representing CHD and/or estimation of prognosis in patients with known coronary artery disease.)IIIaIIbIIIIIIaIIbIII
34Recommendations for Calcium Scoring Methods Measurement of CAC is reasonable for cardiovascular risk assessment in asymptomatic adults at intermediate risk (10% to 20% 10-year risk.Measurement of CAC may be reasonable for cardiovascular risk assessment persons at low to intermediate risk (6% to 10% 10-year risk).Persons at low risk (<6% 10-year risk) should not undergo CAC measurement for cardiovascular risk assessment.BIIIaIIbIIIBIIIaIIbIIIBIIIaIIbIII
35Recommendation for Coronary Computed Tomography Angiography Coronary computed tomography angiography is not recommended for cardiovascular risk assessment in asymptomatic adults.IIIaIIbIII
36Recommendation for Magnetic Resonance Imaging of Plaque Magnetic resonance imaging for detection of vascular plaque is not recommended for cardiovascular risk assessment in asymptomatic adults.IIIaIIbIII
37Special Circumstances and Other Considerations Recommended Approaches to Risk StratificationSpecial Circumstances and Other Considerations
38Risk Assessment Considerations for Patients with Diabetes Mellitus In asymptomatic adults with diabetes, 40 years of age and older, measurement of CAC is reasonable for cardiovascular risk assessment.Measurement of hemoglobin A1C may be considered for cardiovascular risk assessment in asymptomatic adults with diabetes.Stress MPI may be considered for advanced cardiovascular risk assessment in asymptomatic adults with diabetes or when previous risk assessment testing suggests high risk of CHD, such as a CAC score of 400 or greater.BIIIaIIbIIIBIIIaIIbIIIIIIaIIbIII
39Risk Assessment Considerations for Women There is frequent reporting of underutilization of diagnostic and preventive services among female patients. Therefore, it is recommended that:BIIIaIIbIIIA global risk score should be obtained in all asymptomatic women.Family history of CVD should be obtained for cardiovascular risk assessment in all asymptomatic women.BIIIaIIbIII
40Guideline for Cardiovascular Risk Assessment in Asymptomatic Adults Summary of Tests Not Recommended for Assessing CV Risk in Asymptomatic Adults
41Procedural Tests Not Recommended for Asymptomatic Adults ~ Non-cardiac tests ~ Genotype testing (III B)Lipid parameters including lipoproteins, apolipoproteins, particle size and density assessments beyond standard fasting lipid profile (III C)Natriuretic peptide measurement (III B)C-Reactive Protein measurement in asymptomatic high-risk adults (III B)CRP in low-risk men younger than 50 years of age or women 60 years of age (III B)
42Procedural Tests Not Recommended for Asymptomatic Adults (cont Procedural Tests Not Recommended for Asymptomatic Adults (cont.) ~ Cardiac or Vascular tests ~Transthoracic echocardiogram for asymptomatic adults without hypertension (III C)Brachial/peripheral arterial flow mediated dilation studies (III B)Measures of arterial stiffness outside of research settings (III C)Stress echocardiography in low- or intermediate-risk adults (III C)Stress myocardial perfusion imaging in low- or intermediate-risk adults(III C)Coronary artery calcium scoring in low risk adults (<6% 10 year risk) (III B)Coronary computed tomography angiography (CCTA) (III C)Detection of coronary artery plaque by magnetic resonance imaging (III C)
43Limited Data Role of novel biomarkers/imaging studies in risk assessment of selected populations – asymptomaticadultsSelected populationsWomenOlder adultsRacial and ethnic minoritiesDiabetesChronic kidney diseaseGeographic, environmental, neighborhood risk
44Unmet Needs Ascertainment among tests of value Whether test/procedure useful to motivate patients to adhere to recommended interventionsWhether test/procedure useful to guide therapyWhether test/procedure useful as a repeat measure to monitor effects of therapyWhether test/procedure of value in improving health outcomes
45Risk Assessment: Clinical Implications Designed to aid clinician in informed decision-makingabout lifestyle and pharmacologic interventions toreduce CV riskPatients broadly characterized into low-, intermediate-and high-risk subsetsIntensity, type of treatments based on assessments of risk
46Risk Assessment: Clinical Implications (continued) Initial step: Ascertainment of global risk score and family historyof atherosclerotic CV diseaseClass I recommendationsSimple, inexpensiveIf a patient is low-risk – no further testing is necessaryIf a patient is high-risk (CHD, CHD risk equivalents) – he/she iscandidate for intensive preventive interventions – no incremental benefitadded testingIf a patient is intermediate-risk – additional testing can further definerisk statusIIa - benefit exceeds cost and riskIIb - less robust evidence for benefit, but shown to be helpful in selected patientsIII - not recommended for use; has no or limited evidence of benefit, or can cause harm